Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2024-10-22 to 2026-05-07
ROUNDS
3
joined, none as lead
ROUNDS JOINED · USD
$502M
across 3 rounds
CO-INVESTORS
6
named beside it
Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2024-10-22 to 2026-05-07
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Anagram Therapeutics Anagram Therapeutics develops breakthrough orally delivered enzyme therapeutics for rare and life-threatening diseases, primarily targeting malabsorption syndromes and nutrient metabolism disorders. | Funding round Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-05-07 | [ PART ] |
GRIN Therapeutics GRIN Therapeutics develops precision therapeutics targeting neurodevelopmental disorders resulting from NMDA receptor dysfunction, focusing primarily on pediatric patients. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $140M | 2025-05-27 | [ PART ] |
AvenCell Therapeutics A privately held clinical-stage company developing CAR-T therapies | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2024-10-22 | [ PART ] |